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This review aims to provide an overview of models of pharmacist 
prescribing outside and within the UK. Since pharmacist prescribing 
was pioneered in the US, most of the literature available originates 
within the US. Where little information was found in the literature, 
pharmacy societies were contacted to provide further information. 
Both the Australian and South African societies responded; however 
no information was obtained from Canada. Overall, little information 
is available from Canada and South Africa particularly since 
pharmacist prescribing in the latter case has been withdrawn. 
Table 1 accompanies the text below and aims to summarise different 
modes of pharmacist prescribing.
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Pharmacist	prescribing	
in	the	United	States
Pharmacist prescribing has been driven 
by a necessity to improve health care 
delivery, with the inability of pharmacists 
to prescribe resulting in time and cost 
impediments to the delivery of patient 
care. There are two models of pharmacist 
prescribing in the United States (US) 
– dependent or independent prescribing 
authority.1 Dependent prescribing authority 
implies that the pharmacist prescribing 
authority is delegated by an independent 
prescriber, usually a physician, on the 
basis that the pharmacist is capable of 
performing the delegated duties. The two 
have shared responsibility for the patient’s 
overall outcome usually defined through 
a collaborative drug therapy management 
(CDTM) agreement where the physician 
diagnoses and makes treatment decisions 
and the pharmacist selects, monitors, 
modifies or discontinues drug therapy as 
indicated in the agreement. The CDTM 
may take various forms such as general 
written protocols, policies or procedures 
or protocols for each specific patient.2 
Independent prescribing authority implies 
that the prescriber is authorised to 
prescribe all drugs without the supervision 
of another health care professional.1 The 
American College of Clinical Pharmacists 
(ACCP) argues that prescribing within 
current health-care systems can no longer 
be independent due to the complexity of 
drug regimens. It defines prescribing as 
encompassing a broader set of activities 
including selecting, initiating, monitoring, 
continuing, modifying and administering 
medications. The role of a pharmacist within 
a CDTM is consequently advocated since 
this makes use of the expertise of both the 
physician and the pharmacist.
The extent of the pharmacist prescribing 
authority depends on whether the setting 
they are practising is within the remit of 
state or federal law. The state law, which 
changes from one state to another, usually 
favours a model where the pharmacist 
is a dependent prescriber and therefore 
prescribing is based on protocols or 
physician-defined care plans. Many states 
that have introduced pharmacy prescribing 
have opted for this model and include 
California, Kansas, Mississippi, Nevada, 
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New Mexico, North Dakota, Oregon, South 
Dakota, Texas and Washington.1 By the 
end of 200, 8 states allowed pharmacist 
prescribing for various CDTM (compared 
to 14 states at the end of 1996).2 This 
expansion in pharmacist prescribing has 
been due to further evolvement of the 
health-care system including greater 
awareness of patient safety, further data 
showing improved health-care outcomes 
with pharmacist participation, increasing 
age of the population and increased need 
for management of chronic diseases and 
increased patient self-participation and 
shared responsibility for their health 
care.2 To ensure greater cohesiveness, it 
has been recommended that prescribing 
authority should be obtained on a national 
level, embracing all areas of pharmacy 
practice.4 Examples of dependent prescribing 
authority may be found in both primary 
and secondary care. In ambulatory care 
settings, pharmacists assume responsibility 
for the management of chronic conditions 
such as hypertension, asthma, diabetes, 
hyperlipidaemia and psychiatric disorders. 
Within a hospital environment, pharmacists 
may adjust infusions of heparin therapy 
against a written protocol agreed by a 
physician or assume responsibility for in- 
and out-patient pain management, including 
prescribing of adjunct therapy such as 
anti-emetics, antihistamines, laxatives and 
benzodiazepines.6 Hospital pharmacists may 
also be involved in automatic therapeutic 
substitution to ensure that only drugs on 
the formulary are prescribed.6 The American 
Society of Health Care System Pharmacists 
(ASHP) has included pharmacist prescribing 
under CDTMs as one of its goals in the 201 
initiative. For hospital inpatients to achieve 
best use of medicines it aims to have 90% 
of hospitals having pharmacists manage 
medication therapy in collaboration with 
other members of the healthcare team. This 
also holds for non-hospital patients such as 
clinic and home-care settings. Independent 
prescriptive authority at state level is in 
place in Florida, though pharmacists may 
only prescribe from a limited formulary 
and against strict protocols including 
anti-emetic preparations, antidiarrhoeals 
and smoking cessation products.1,,8 There 
has however been little updating of the 
formulary and consequently many of the 
items on the formulary have become over-
the-counter medicines.6 
The federal government is keener to 
expand the prescribing authority of the 
pharmacist and move towards pharmacist 
independent prescribing. This may be 
implemented within a federal institution 
irrespective of the state laws and 
regulations.1 A directive of the Veteran 
Affairs (VA) Department lays this down 
clearly ...”Because states cannot regulate 
the activities of the federal government, 
or its employees when acting within the 
scope of their federal employment, except 
by congressional consent, state laws and 
regulations relating to medication orders 
and prescriptions do not affect scope of 
practice statements under this directive.” 9 
Within the VA department, clinical pharmacy 
specialists have worked as independent 
providers prescribing medicines, reviewing 
and ordering laboratory tests, performing 
venepuncture, analyzing lab and diagnostic 
test data, performing physical examinations 
and assisting in management of medical 
emergencies, adverse drug reactions, acute 
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Table	1.	A	summary	of	different	prescribing	models
Country Prescribing	model Description
US Dependent prescribing
Authority is delegated to the pharmacist by an independent prescriber (usually 
a physician). The shared responsibility is described through a collaborative drug 
therapy management. Model favoured by the state law.
Independent prescribing The pharmacist is allowed to prescribe all drugs without the supervision of another health care professional. Model favoured by the federal law.
South Africa
Providing prescription only 
medication at pharmacist’s 
own discretion
Aimed at making medicine more accessible to rural communities. This model has 
been withdrawn and is not currently in place though its status is being reviewed.
Canada Dependent or delegate prescribing
Prescribing based on a collaborative therapy agreement with a physician. 
Model favoured by most provinces.
Independent prescribing Prescribing outwith a collaborative agreement which is limited mainly to emergency contraception.
Australia None Still under development.
UK Supplementary prescribing
The pharmacist may prescribe for a diagnosed condition, within the agreement 
set out with the independent prescriber and the patient in a Clinical Mangement 
Plan (CMP). 
Independent prescribing
The pharmacist may prescribe any drug independently, whether for a diagnosed 
or undiagnosed condition, without the need for a CMP or partnership with an 
independent prescriber.
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and chronic conditions and administering 
medicines.10 Totally independent prescribing 
authority was pioneered by Florida VA 
pharmacists in outpatient clinics.11 This 
expanded role of the pharmacy specialist 
has been used as a model for other federal 
agencies such as the US Army and the 
Indian Health Service.1,12 One of the main 
barriers to pharmacist prescribing in the 
US has been the pharmaceutical industry 
since pharmacists were perceived as more 
likely to prescribe generics than doctors.6 
The American College of Physicians and 
American Society of Internal Medicine 
have issued a position statement on 
the expanding role of the pharmacist in 
which reference is made to pharmacist 
prescribing.1 This supports physician-
directed pharmacist-physician collaborative 
practice agreements but limits these to 
the involvement of the pharmacist in 
patient education and hospital rounds. It 
categorically states, “...we need to ensure 
that physicians control prescriptive rights and 
have the final approval over all patient care 
decisions.” It goes on to comment about 
pharmacist independent prescribing and 
does not support this, claiming that there 
is no evidence that this will benefit the 
patient and that pharmacists are not trained 
to initiate therapy. It again emphasises that 
“this is clearly an area that should remain 
under physician authority.”
Prior to the expansion of this role of 
the pharmacist, in the early 1980s, studies 
were undertaken to prove the advantages 
of pharmacists to a clinical service. This 
extended role of the pharmacist within a 
clinical service is now generally accepted as 
an integral part of health care and looking 
into the cost effectiveness or cost benefit 
comparisons with physician prescribing 
is no longer seen as a priority in many 
institutions.6 Training for pharmacists to 
prescribe is not centralised and pharmacist 
prescribers need to be credentialed within 
their employing institution.14
Pharmacist	prescribing	in	South	Africa
Pharmacists working in rural 
communities in South Africa were previously 
issued with a permit 22A12 allowing them to 
provide prescription only medicines based 
on their own discretion. This was issued 
following completion of the Primary Care 
Drug Therapy Course (PCDT). The aim was 
to provide a service to patients in rural 
communities where most patients go to the 
pharmacy before seeing a doctor and usually 
have no prescription. At this point, the 
main barrier towards expanding the number 
of medicines that may be dispensed by the 
pharmacist was the medical profession who 
seemed to show “...fierce and organised 
resistance.” 1 More recently, the Department 
of Health in South Africa has withdrawn 
all these permits from pharmacists and 
the South African Pharmacy Council is now 
looking at ways to take the PCDT training 
forward. [personal communication]
Pharmacist	prescribing	in	Canada
Pharmacist prescribing in Canada 
is limited and varies across provinces. 
Where pharmacist prescribing occurs, 
this is mainly dependent or delegated 
prescribing based on a collaborative 
prescribing model involving an agreement 
between a pharmacist and a physician.16 
Some states such as British Columbia, 
Saskatchewan and Quebec, support 
independent pharmacist prescribing of 
emergency contraception.16 The Canadian 
Society of Hospital Pharmacists advocates 
collaborative prescribing within health care 
facilities arguing that this makes use of 
the diagnostic expertise of the physician 
and the pharmacotherapy expertise of 
the pharmacist.1 It also claims that this 
will provide improved patient outcomes 
and increases the successful and efficient 
delivery of pharmaceutical care.18
Pharmacist	prescribing	in	Australia
Pharmacist prescribing has been a topic 
of discussion and debate in Australia with a 
perception that Australia has been slow to 
catch on to this approach to prescribing.19 
The Society of Hospital Pharmacists of 
Australia supports extending prescribing 
rights to pharmacists provided that these 
are competency based.20 Extension of 
the roles of and services provided by 
pharmacists are being proposed to make 
better use of the pharmacists’ knowledge 
and improve consumer access to medicines 
without compromising patient safety.21 
Pharmacist	prescribing	in	the	UK
The main drive towards the development 
of pharmacist prescribing in the UK, has 
been a desire to make greater use of 
the skills and specialisation of different 
health care professionals by creating a 
more flexible system to prescribe, supply 
and administer medicines.  This was the 
focus of the final ‘Crown Report’ published 
in 1999 which made recommendations 
on the potential expansion of prescribing 
roles of health care professionals.22,2 This 
subsequently led to changes in legislation 
resulting in extending prescribing privileges 
to pharmacists. 
There are two models of pharmacist 
prescribing in the UK: pharmacist 
supplementary prescribing (previously 
referred to as dependent prescribing in the 
‘Crown Report’) and pharmacist independent 
prescribing. Legislation was amended in 
200 to permit pharmacist supplementary 
prescribing (SP); supplementary prescribing 
is defined as: “A voluntary partnership 
between the responsible independent 
prescriber and a supplementary prescriber, 
to implement an agreed patient specific 
clinical management plan with the patient’s 
agreement, particularly but not only in 
relation to prescribing for a specific non-
acute medical condition or health need 
affecting the patient.”24 The clinical 
management plan (CMP) is central to 
supplementary prescribing since it forms the 
basis for patient management within the 
agreed framework. It needs to be drawn up 
for each patient with agreement reached 
between the independent prescriber, the 
supplementary prescriber and the individual 
patient. The clinical management plan must 
make reference to the class(es) of drug(s) 
or drug(s) to be prescribed. Independent 
pharmacist prescribing (IP) was introduced 
in May 2006 following amendments to 
legislation; an independent prescriber is 
defined as: “...a practitioner responsible for 
the assessment of patients with undiagnosed 
or diagnosed conditions and for decisions 
about the clinical management required, 
including prescribing.”2 
As may be expected, due to the 
novelty of the subject, there is not much 
evidence available around pharmacist 
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prescribing in the UK. This has been the 
subject of a recently published review26 
where the authors aimed to summarise 
the literature to date on pharmacist 
prescribing and to explore the main areas 
of care and practice settings including 
any benefits and limitations. Tonna et 
al report that the delivery of pharmacist 
SP and plans for service development 
were identified in different health care 
settings which may be divided into four 
models: community, hospital, primary care 
settings and the primary/secondary care 
interface.26,2 Narrative reports show that 
within secondary care, SP was being applied 
across various specialities including the 
adjustment of aminoglycoside dosages as 
part of therapeutic drug monitoring, to 
facilitate patient discharge on a cardiac 
unit, and as part of a clinical nutrition 
team. Reports of pharmacist-led prescribing 
clinics also emerge from primary care with 
pharmacist involved in hypertension and 
clinical risk reduction clinics. 
Initial research reports that almost 0% 
of pharmacist supplementary prescribers 
self-reported prescribing with pharmacists 
reporting both benefits of and barriers to 
implementing SP.28,29  
Research involving other health 
care professionals has indicated that 
•	 Pharmacist prescribing was pioneered in the US. Recent developments within 
the UK also allow pharmacist prescribing.
•	 The main driving force has been a need for greater patient access to 
medication and a better use of the pharmacist’s skills.
•	 There are two main forms of pharmacist prescribing: dependent or 
supplementary prescribing, where collaboration or agreement with a physician 
is essential, and independent prescribing without the need for formal 
collaboration with another health care professional.
•	 To be registered prescribers, pharmacists need to complete accredited training 
programmes. Accreditation is nation-wide in the UK while this varies between 
states and institutions in the US.
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encroachment of traditional roles likely 
to occur due to the advent of pharmacist 
prescribing may also be a barrier.0,1 A small 
scale study has concluded that patients 
are likely to favourably accept pharmacist 
prescribing2, with another study showing 
potential favourable outcomes of pharmacist 
prescribing.  There is no research yet 
available about practices involving 
pharmacist independent prescribing.
Most of the literature from the UK 
focuses on pharmacists’ perceptions of 
supplementary prescribing, with little 
information referring to other stakeholders, 
including patients. There is also limited 
published research focusing on clinical and 
economic outcomes of pharmacist SP. 
Conclusion
With the exception of the US, where 
pharmacist prescribing has been pioneered, 
this is a rapidly changing aspect of 
pharmacy practice.  This is particularly 
so in the UK, where the recent advent 
of pharmacist IP is likely to create more 
opportunities for pharmacy involvement and 
expansion of the pharmacist role. It is likely 
that the research and the body of evidence 
around pharmacist prescribing will therefore 
expand over the coming years.
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Prescribing and dispensing checklists
Prescriber’s	Prescription	Checklist
Writing must be in ink
Writing must be legible
Name and signature of prescriber
Address and contact details of prescriber
Medical Council registration number
Full name and age of patient
Locality of patient
Name, dose and dosage form of medicine
Quantity of medicine
Duration of treatment
Instructions on how to take medicine
Period of duration for a repeat prescription
Instructions to indicate when the patient can only 
be administered a branded product
Pharmacist’s	Prescription	Checklist
Prescription is in ink and legible
Date of issue of prescription
Name, address and other details of prescriber
Medical Council registration number 
Signature of prescriber
Full name, age and locality of patient
Name, dose, dosage form of medicine
Quantity of medicine and duration of treatment
Instructions on how to take medicine
Period of duration for a repeat prescription
Expiry of 10 days for antibiotics
Expiry of 6 months unless repeat prescriptions
Indications of use or exhaustion of prescription
Possibility or necessity of substitution
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